Interestingly, GLP-1RA antidiabetic drugs have shown a distinct effect in reducing the incidence of stroke and enhancing neuroprotection in both pre-clinical and clinical studies (80, 81)
39 Long-term human data did not support this claim, however, and the boxed warning was later removed
With more data available, the FDA said the evidence does not support a connection
This accelerated timeline is directly attributable to the glucagon receptor activation, which adds the thermogenic and lipolytic effects that single and dual agonists lack
In rare cases, serious side effects such as pancreatitis (inflammation of the pancreas), gallbladder problems, severe abdominal pain, or signs of an allergic reaction can also require discontinuation